[1] |
YU Qiaoling, ZHAI Weiwei, LIU Ping, QIU Bo, WU Huizhen.
Research progress in plasma concentration monitoring of rivaroxaban
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 809-817.
|
[2] |
WU Zhiyong, LIU Bingrong, LI Bin, TANG Rui.
Value of red blood cell distribution width in predicting early poor neurologic improvement after intravenous thrombolysis in patients with ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 307-314.
|
[3] |
TAO Yanyan, TANG Yajie, WANG Lili, WANG Fangli, LU Guoyu, FAN Fangtian.
Clinical characteristics of anticoagulant rodenticide poisoning in northern Anhui analysis of the effect of the vitamin K1 medication regimen on the efficacy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1263-1268.
|
[4] |
CHANG Shufu .
Progress of medical treatment of coronary heart disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 405-408.
|
[5] |
LU Xiya, LI Yuxing, LI Wenzhi, PENG Yuanyuan, HU Yi, WAN Li, CHEN Bilian.
Analysis of prescribing of antiplatelet drug in patients with coronary heart disease in department of geriatrics
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1285-1291.
|
[6] |
XU Honglei, XU Bingxin, ZU Qing, ZHAO Yan, GAO Pengfei, YU Yang.
Effects of CYP2C19 gene polymorphism on the clinical prognosis of clopidogrel in elderly patients with acute cerebral infarction
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1014-1020.
|
[7] |
QIN Wenjie, YANG Zhiling, CAO Ailin, GAO Hang, JIANG Xianrui, SHEN Yue, QIAN Jiao.
Advances in the study of new oral anticoagulants in cancer-associated venous thromboembolism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 823-828.
|
[8] |
ZHANG Tengyue, YANG Guangshan, MA Kelong, FAN Pingsheng.
Clinical study of anticoagulant therapy on hypercoagulable state and anti-tumor metastasis in advanced gastric cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 433-439.
|
[9] |
YANG Rui, XU Haisha, ZHANG Zanling, QU Jian, LI Juan, PENG Shiqi, DAI Yuxin, QU Qiang.
Effect of drug interaction on anticoagulant strength of warfarin
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(12): 1426-1431.
|
[10] |
YIN Shuo, YU Yue, GUO Xing-lei, LIU Gao-feng.
Effects of traditional Chinese medicine on the role of warfarin and the mechanisms
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 327-334.
|
[11] |
LIU Jun, XU Hang.
Evaluation of warfarin anticoagulant management by clinic pharmacists on patients with cardiac valve surgery
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1021-1024.
|
[12] |
ZHANG Xia, KE Yong-sheng.
Clinical research of new type P2Y12 Receptor inhibitor ticagrelor
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(4): 459-464.
|
[13] |
JIA Liang-Liang, KE Yong-sheng.
Antiplatelet strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 1074-1080.
|
[14] |
TAN Sheng-lan, ZHOU Xin-min, PENG Juan, ZHANG Wei, LIU Zhao-qian, ZHOU Hong-hao, LI Zhi.
Reversal of the anticoagulant effect of dabigatran etexilate
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(12): 1413-1418.
|
[15] |
WU Ya-ning, ZHAO Di, LI Ning, CHEN Xi-jing.
Progression of ADP receptor inhibitors antiplatelet drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(12): 1434-1440.
|